Clinical trial
Selective Dose Escalation for Esophageal Cancer
NCT00139633 · The Oregon Clinic, Other · Unknown status
Key facts
| NCT number | NCT00139633 |
|---|---|
| Title | Selective Dose Escalation for Esophageal Cancer |
| Official title | Phase II Selective Dose Escalation of Chemoradiotherapy for Esophageal Cancer |
| Lead sponsor | The Oregon Clinic, Other |
| Collaborators | Bristol-Myers Squibb Industry MedImmune LLC |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, 5FU, Taxol and radiation |
| Enrollment | 25 |
| Start date | Jul 1, 2000 |
| Completion | Jun 1, 2005 |
| First posted | Aug 31, 2005 |
| Last update posted | Aug 31, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: